BRPI0820960B8 - composição, composição farmacêutica, e uso da composição - Google Patents

composição, composição farmacêutica, e uso da composição

Info

Publication number
BRPI0820960B8
BRPI0820960B8 BRPI0820960A BRPI0820960A BRPI0820960B8 BR PI0820960 B8 BRPI0820960 B8 BR PI0820960B8 BR PI0820960 A BRPI0820960 A BR PI0820960A BR PI0820960 A BRPI0820960 A BR PI0820960A BR PI0820960 B8 BRPI0820960 B8 BR PI0820960B8
Authority
BR
Brazil
Prior art keywords
composition
antigen
immune response
enhancing
pharmaceutical
Prior art date
Application number
BRPI0820960A
Other languages
English (en)
Inventor
Serra Vincent
Original Assignee
Abivax
Wittycell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax, Wittycell filed Critical Abivax
Publication of BRPI0820960A2 publication Critical patent/BRPI0820960A2/pt
Publication of BRPI0820960B1 publication Critical patent/BRPI0820960B1/pt
Publication of BRPI0820960B8 publication Critical patent/BRPI0820960B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

composição. são aqui fornecidas composições compreendendo o composto da fórmula. também fornecidos são métodos de melhorar uma resposta imune de um indivíduo a um antígeno administrando o antígeno e a composição. a melhor resposta imune pode ser uma resposta imune humoral, uma resposta de célula t cd4+, uma resposta de célula t cd8+ o resultar na ativação de células que apresentam antígeno. métodos de melhorar a resposta imune por administração intramuscular de um antígeno e a composição incluindo o composto da fórmula i também são fornecidos.
BRPI0820960A 2007-12-05 2008-12-05 composição, composição farmacêutica, e uso da composição BRPI0820960B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99246007P 2007-12-05 2007-12-05
PCT/IB2008/003945 WO2009101475A2 (en) 2007-12-05 2008-12-05 Compositions for and methods of enhancing the immune response to antigens

Publications (3)

Publication Number Publication Date
BRPI0820960A2 BRPI0820960A2 (pt) 2017-05-09
BRPI0820960B1 BRPI0820960B1 (pt) 2020-04-07
BRPI0820960B8 true BRPI0820960B8 (pt) 2021-05-25

Family

ID=40788916

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820960A BRPI0820960B8 (pt) 2007-12-05 2008-12-05 composição, composição farmacêutica, e uso da composição

Country Status (14)

Country Link
US (2) US8207135B2 (pt)
EP (1) EP2231145B1 (pt)
JP (1) JP5813953B2 (pt)
KR (1) KR101566847B1 (pt)
CN (1) CN101917985B (pt)
AU (1) AU2008350531B2 (pt)
BR (1) BRPI0820960B8 (pt)
CA (1) CA2708246C (pt)
DK (1) DK2231145T3 (pt)
ES (1) ES2525127T3 (pt)
PT (1) PT2231145E (pt)
RU (1) RU2537188C2 (pt)
WO (1) WO2009101475A2 (pt)
ZA (1) ZA201003964B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
EP2842961B1 (en) 2012-04-26 2016-12-14 Riken New carbamate glycolipid and use thereof
US9994605B2 (en) 2014-03-13 2018-06-12 Universitaet Basel Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein
CA2996073A1 (en) * 2015-09-16 2017-03-23 Universitat Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
ES2999021T3 (en) * 2016-09-14 2025-02-24 Abivax Combinations including abx196 for the treatment of cancer
EP3681512B1 (en) 2017-09-13 2021-08-04 Abivax Abx196 for use in the treatment of bladder cancer
CN110241060B (zh) 2019-08-02 2020-10-09 青岛农业大学 一种水貂肺炎克雷伯氏菌及其应用
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pt) 1992-07-16 1995-11-01 Kirin Brewery
AU683026B2 (en) * 1992-10-22 1997-10-30 Kirin Pharma Kabushiki Kaisha Novel shingoglycolipid and use thereof
EP0694558B1 (en) 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
CZ298895A3 (en) * 1993-05-14 1996-04-17 Cytel Corp Compound analogous to sialyl lex, pharmaceutical composition containing thereof and process for preparing lactosammonium salt
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
CA2280130C (en) 1997-02-05 2007-12-18 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing sphingoglycolipid and process for preparing them
JP3495740B2 (ja) 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
US6492337B1 (en) 1997-12-30 2002-12-10 A+ Science Ab Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complication
DE69943314D1 (de) 1998-02-12 2011-05-12 Kapil N Bhalla Sphingolipid-derivate und verfahren zu deren verwendung
AU2001252599A1 (en) * 2000-04-28 2001-11-12 Orient Cancer Therapy Co., Ltd. Remedies for cancer
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AR034413A1 (es) 2000-08-25 2004-02-25 Nestor Abel Chamoles Metodo para determinar la actividad de las enzimas lisosomales
EP1434859A2 (en) * 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
KR20050043736A (ko) * 2001-11-06 2005-05-11 오리엔트 캔서 세라피 컴퍼니 리미티드 항암 조성물
US7273853B2 (en) 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
AU2003251518B2 (en) * 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
CA2560969A1 (en) * 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
CA2578052C (en) 2004-09-03 2013-08-13 The University Of Chicago Methods of activating nkt cells
US7534434B2 (en) 2004-12-28 2009-05-19 The Rockefeller University Glycolipids and analogues thereof as antigens for NK T cells
PT1848813E (pt) 2005-01-28 2013-07-15 Scripps Research Inst Activação de glicolípidos bacterianos de células nkt restritas ao cd1d
KR100764678B1 (ko) * 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
EP1776963A1 (en) * 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
BRPI0617687A2 (pt) 2005-10-25 2011-08-02 Ludwig Inst Cancer Res composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica
DK2056842T3 (da) * 2006-04-07 2013-01-14 Univ Chicago Modificeret galactosylceramid til behandling af cancerøse sygdomme
CN101426523B (zh) 2006-04-27 2013-03-27 财团法人首尔大学校产学协力财团 基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗
EP2040541B1 (en) 2006-06-30 2016-03-23 The Scripps Research Institute Adjuvants and methods of use
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
JP5809560B2 (ja) 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物

Also Published As

Publication number Publication date
CA2708246A1 (en) 2009-08-20
CA2708246C (en) 2016-05-24
US20100322952A1 (en) 2010-12-23
CN101917985A (zh) 2010-12-15
WO2009101475A3 (en) 2009-10-22
BRPI0820960A2 (pt) 2017-05-09
ES2525127T3 (es) 2014-12-17
US20090162385A1 (en) 2009-06-25
RU2010127339A (ru) 2012-01-10
BRPI0820960B1 (pt) 2020-04-07
KR101566847B1 (ko) 2015-11-06
PT2231145E (pt) 2014-12-23
JP2011506306A (ja) 2011-03-03
DK2231145T3 (en) 2014-12-08
US8207135B2 (en) 2012-06-26
EP2231145B1 (en) 2014-09-17
WO2009101475A2 (en) 2009-08-20
AU2008350531B2 (en) 2014-01-23
JP5813953B2 (ja) 2015-11-17
CN101917985B (zh) 2014-07-02
EP2231145A2 (en) 2010-09-29
US8211861B2 (en) 2012-07-03
KR20100094556A (ko) 2010-08-26
ZA201003964B (en) 2011-02-23
AU2008350531A1 (en) 2009-08-20
RU2537188C2 (ru) 2014-12-27

Similar Documents

Publication Publication Date Title
BRPI0820960B8 (pt) composição, composição farmacêutica, e uso da composição
BRPI0515316A (pt) compostos de imidazoquinolina
CO6751288A2 (es) Composición antigénica de micobacteria
AR125327A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
BRPI0510430A (pt) composições e métodos para vacinação mucosal
BR112013002940A2 (pt) adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
NO20064781L (no) Fremgangsmater og adjuvanser for a forbedre immunresponser mot vaksiner og fremgangsmater for anvendelse
BR112021019558A2 (pt) Composições e métodos para preparar composições de células t e usos dos mesmos
BRPI0411505A (pt) uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa
BRPI0510394A (pt) inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1
AR059772A1 (es) Composiciones que incuyen hemaglutinina metodos de elaboracion y metodos de uso de las mismas
ECSP11011115A (es) Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t
AR085633A1 (es) Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
BR112012009962A2 (pt) método para a proliferação de células tantígeno específicas.
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
MX2009009168A (es) Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
BRPI0607605A2 (pt) moléculas imunogênicas
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
BRPI0820258B8 (pt) composto, composições de vacina, e, uso de um composto
TR201818784T4 (tr) Selenyum İle Kombinasyon Halinde Aronia Sp.'nin Bir Ekstraktını İçeren Bağışık Uyarıcı Terkip
SG10201901391RA (en) Induction of il-12 using immunotherapy

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABIVAX (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF